Changing Treatment Paradigms in Type 1 Diabetes: Role of Anti-CD3 Targeted Therapy -- Anti-CD3 Monoclonal Antibodies to Prevent/Delay Onset of Type 1 Diabetes - a podcast by ReachMD

CME credits: 0.50

Valid until: 31-05-2022

Claim your CME credit at https://reachmd.com/programs/cme/changing-treatment-paradigms-type-1-diabetes-role-anti-cd3-targeted-therapy-anti-cd3-monoclonal-antibodies-preventdelay-onset-type-1-diabetes/12599/

Experts in the immunopathology of type 1 diabetes consider the potential role of monoclonal antibodies, disease modifying agents, and other agents to prevent or delay the onset of clinical disease. Particular emphasis will be placed on the CD3 cell surface marker and anti-CD3 monoclonal antibodies, which has been shown to slow progression to clinical type 1 diabetes in high risk persons.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD